Ardelyx (ARDX) Stock Analysis & AI Equity Report
Ardelyx (ARDX) overview
Ardelyx (ARDX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 407m and operating profit of USD -41.0m; the year-end share price was 5.83 USD and market capitalisation was USD 1,425m. Ardelyx is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ardelyx's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ardelyx
Ardelyx develops and commercializes medicines for unmet medical needs. It markets IBSRELA, an oral tenapanor therapy approved in the United States for adults with irritable bowel syndrome with constipation, and XPHOZAH, approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company also develops a next-generation NHE3 inhibitor.
Generate the Ardelyx report
Ardelyx is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ardelyx and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ardelyx
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.